Search results
Is Pfizer the Best Dividend Stock for You? | The Motley Fool
The Motley Fool· 4 days agoThe pandemic-influenced revenue gusher from which pharmaceutical giant Pfizer (PFE 1.63%) benefitted...
Column: US appellate courts split on threshold for lawsuits challenging diversity programs
Reuters· 7 hours agoThe Atlanta-based 11th U.S. Circuit Court of Appeals, as my colleague Mike Scarcella reported,...
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
Motley Fool via Yahoo Finance· 7 days agoAs two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca...
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
FOX Business· 4 days agoPfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the...
Is Pfizer the Best Dividend Stock for You?
Motley Fool via Yahoo Finance· 4 days agoThe pandemic-influenced revenue gusher from which pharmaceutical giant Pfizer (NYSE: PFE) benefitted a few years ago has trickled down to a small stream....
GSK shares fall 9% in wake of Zantac court ruling
Pharmaceutical Technology via Yahoo Finance· 17 hours agoPfizer, Boehringer Ingelheim, Sanofi, and Patheon are also implicated in the cases. In 2020, the US Food and Drug Administration (FDA) ordered the...
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock | The Motley Fool
The Motley Fool· 7 days agoAs two of the world's largest and most prolific drugmakers, Pfizer (PFE -1.70%) and AstraZeneca (AZN...
California State Teachers Retirement System Increases Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 2 days agoCalifornia State Teachers Retirement System grew its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 1.5% during the fourth quarter, according to its most recent 13F filing ...
Takeda and Pfizer report positive Phase III HD21 trial of ADCETRIS
Clinical Trials Arena via Yahoo Finance· 2 days agoTakeda and Pfizer have announced a positive Phase III HD21 trial, evaluating ADCETRIS (brentuximab...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 6 days agoPfizer stock is lingering just above its 50-day line after the company beat first-quarter sales...
